Economic evaluation of HBV vaccination: A systematic review of recent publications (2000-2013).
To conduct a systematic review of the economic evaluations (EE) of HBV vaccination, taking also into account the studies published in the new millennium.



An extensive scientific literature review was conducted using two electronic medical journal databases: Scopus and PubMed engines for published studies on EE of HBV vaccination.



22 articles were reviewed, 9, 5 and 8 cost-effectiveness, cost-benefit and cost-utility analysis, respectively. Studies were mainly concerning EE of universal vaccination (UV), mostly with regards to low or low-medium income countries. For high income countries, EE were focused on the possible implementation of HBV vaccination in particular settings, such as diabetic, renal and other chronic conditions care, as well as infectious diseasesUV has usually a very good cost-effectiveness ratio (80%), ranging from cost-saving (China) or few Euro per LY/QALY gained (in Thailand, and Vietnam) to 630.00$/QALY in USA (Asian and Pacific Islands) Moreover, EE of HBV vaccination are favorable in the infectious diseases field as well as for chronic conditions. In relation to diabetes the studies gave controversial results.



This systematic review highlighted the importance of introducing HBV vaccination not only for infant UV program but also for other settings in which patients are people affected by communicable and non-communicable diseases.
a Department of Public Health and Infectious Diseases , Sapienza University of Rome , Rome , Italy.
Giuseppe
G
La Torre
a Department of Public Health and Infectious Diseases , Sapienza University of Rome , Rome , Italy.
Alice
A
Mannocci
a Department of Public Health and Infectious Diseases , Sapienza University of Rome , Rome , Italy.
Rosella
R
Saulle
a Department of Public Health and Infectious Diseases , Sapienza University of Rome , Rome , Italy.
Vittoria
V
Colamesta
a Department of Public Health and Infectious Diseases , Sapienza University of Rome , Rome , Italy.
Angela
A
Meggiolaro
a Department of Public Health and Infectious Diseases , Sapienza University of Rome , Rome , Italy.
Daniele
D
Mipatrini
a Department of Public Health and Infectious Diseases , Sapienza University of Rome , Rome , Italy.
Alessandra
A
Sinopoli
D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D014943:Global Health; D006509:Hepatitis B / Q000191:economics* / Q000453:epidemiology / Q000517:prevention & control*; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000191:economics* / Q000276:immunology*; D006801:Humans
D017325:Hepatitis B Vaccines
HBV vaccination; cost benefit; cost-effectiveness; cost-utility; economic evaluation